Fingolimod, a first-line, once-daily oral disease-modifying therapy for relapsing-remitting multiple sclerosis, has the lowest cost per relapse avoided compared with other first-line agents.
Rashad Carlton, PharmD, MSPH
Advertisement
Articles by Rashad Carlton, PharmD, MSPH
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Fingolimod in Treating Patients With Relapsing-Remitting Multiple Sclerosis
Published: December 12th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Reformulated Ranitidine After 5-Year Absence
2
Fun Fact: Coffee Could Reduce Feelings of Depression
3
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
4
Application of the Age-Friendly 4M’s Movement Across Different Areas of Pharmacy
5
